Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Moderna (MRNA)
William Blair analyst Myles Minter maintained a Hold rating on Moderna yesterday. The company’s shares closed last Friday at $47.44, close to its 52-week low of $29.25.
According to TipRanks.com, Minter is a 5-star analyst with an average return of 29.8% and a 54.9% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc.
Currently, the analyst consensus on Moderna is a Hold with an average price target of $44.61, which is a -12.1% downside from current levels. In a report issued on June 1, Bernstein also maintained a Hold rating on the stock.
